One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.

Trump’s Moves to Upend Federal Bureaucracy Touch Off Fear and Confusion Agencies are gripped with uncertainty about how to implement a blizzard of President Trump’s new policies as workers ...

Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer and dementia, a sweeping new study shows.

Jan. 23, 2025 — With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Shares of Danish pharmaceutical giant Novo Nordisk surged close to 14% on Friday after the company announced positive results from early-stage trials for its once-weekly obesity treatment, amycretin.

One of the glaring numbers in this loss for the Tigers is in the turnover column. Ball security has been an issue for them this season and it continued against the Aggies. After finishing the ...

Novo Nordisk’s subcutaneous form of amycretin achieved estimated weight loss of 22% at six months in a Phase 1b/2a clinical trial, the Danish company said Friday.

If you are underweight, you should not follow a weight-loss plan. The volunteers reduced their waist sizes by an average of 1 inch for every 4lb (1.81kg) they lost. So if you lose 1lb (0.45kg ...

Israeli Forces in Jenin were reportedly targeted by Palestinian fighters with explosive devices. This even as Israeli troops burn homes and issued evacuation orders to residents in Jenin. Israeli chief of staff Herzi Halevi said IDF’s decision to go in forcefully against Jenin refugee camp was absolutely right.